<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Enfuvirtide</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Enfuvirtide">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Enfuvirtide</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Enfuvirtide</b> (INN) is an HIV fusion inhibitor, the first of a class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name <b>Fuzeon</b> (Roche).</p>

<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Enfuvirtide</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Enfuvirtid.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Enfuvirtid.svg.png" data-file-width="3816" data-file-height="362" data-file-type="drawing" height="27" width="280"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Fuzeon</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/enfuvirtide.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/enfuvirtide.html'" tppabs="https://www.drugs.com/monograph/enfuvirtide.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">EU</abbr></small><span>&nbsp;</span>EMA:<span>&nbsp;</span><span><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Enfuvirtide  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Enfuvirtide'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Enfuvirtide" class="external text external">by INN</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>B2<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>B (No risk in non-human studies)<span> </span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>Subcutaneous (SC)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>J05AX07<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=J05AX07  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=J05AX07'" tppabs="https://www.whocc.no/atc_ddd_index/?code=J05AX07" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>S4 (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">CA</abbr></small>:<span> </span> ℞-only<span> </span></li>
<li><small><abbr class="country-name">UK</abbr>:</small><span> </span>POM (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>84.3% (SC)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Protein binding</th><td>92%</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>Hepatic</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>3.8 hours</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Excretion</th><td>unknown</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=159519-65-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=159519-65-0'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=159519-65-0" class="external text external">159519-65-0</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem <span style="font-weight:normal"><abbr>CID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/16130199  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/16130199'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/16130199" class="external text external">16130199</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00109  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00109'" tppabs="https://www.drugbank.ca/drugs/DB00109" class="external text external">DB00109</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.16743716.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.16743716.html'" tppabs="http://www.chemspider.com/Chemical-Structure.16743716.html" class="external text external">16743716</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=19OWO1T3ZE  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=19OWO1T3ZE'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=19OWO1T3ZE" class="external text external">19OWO1T3ZE</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D02499  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D02499'" tppabs="https://www.kegg.jp/entry/D02499" class="external text external">D02499</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEBI</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:608828  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:608828'" tppabs="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:608828" class="external text external">CHEBI:608828</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL525076  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL525076'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL525076" class="external text external">ChEMBL525076</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">NIAID ChemDB</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemdb.niaid.nih.gov/CompoundDetails.aspx?AIDSNO=059486  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemdb.niaid.nih.gov/CompoundDetails.aspx?AIDSNO=059486'" tppabs="https://chemdb.niaid.nih.gov/CompoundDetails.aspx?AIDSNO=059486" class="external text external">059486</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID20166672  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID20166672'" tppabs="https://comptox.epa.gov/dashboard/DTXSID20166672" class="external text external">DTXSID20166672</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.169.201  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.169.201'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.169.201" class="external text external">100.169.201</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>204</sub><span>H</span><sub>301</sub><span>N</span><sub>51</sub><span>O</span><sub>64</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">4<span style="margin-left:.25em;">491</span>.945</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">3D model (JSmol)</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemapps.stolaf.edu/jmol/jmol.php?model=CC%5BC%40H%5D%28C%29%5BC%40%40H%5D%28C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CO%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29N%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28%3DO%29N%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29N%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29N%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CCCCN%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28%3DO%29N%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29N%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28C%29C%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28C%29C%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28C%29C%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CCCCN%29C%28%3DO%29N%5BC%40%40H%5D%28Cc1c%5BnH%5Dc2c1cccc2%29C%28%3DO%29N%5BC%40%40H%5D%28C%29C%28%3DO%29N%5BC%40%40H%5D%28CO%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28C%29C%29C%28%3DO%29N%5BC%40%40H%5D%28Cc3c%5BnH%5Dc4c3cccc4%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28%3DO%29N%29C%28%3DO%29N%5BC%40%40H%5D%28Cc5c%5BnH%5Dc6c5cccc6%29C%28%3DO%29N%5BC%40%40H%5D%28Cc7ccccc7%29C%28%3DO%29N%29NC%28%3DO%29%5BC%40H%5D%28CC%28C%29C%29NC%28%3DO%29%5BC%40H%5D%28CO%29NC%28%3DO%29%5BC%40H%5D%28Cc8cnc%5BnH%5D8%29NC%28%3DO%29%5BC%40H%5D%28%5BC%40%40H%5D%28C%29CC%29NC%28%3DO%29%5BC%40H%5D%28CC%28C%29C%29NC%28%3DO%29%5BC%40H%5D%28CO%29NC%28%3DO%29%5BC%40H%5D%28%5BC%40%40H%5D%28C%29O%29NC%28%3DO%29%5BC%40H%5D%28Cc9ccc%28cc9%29O%29NC%28%3DO%29C  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemapps.stolaf.edu/jmol/jmol.php?model=CC%5BC%40H%5D%28C%29%5BC%40%40H%5D%28C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CO%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29N%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28%3DO%29N%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29N%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29N%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CCCCN%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28%3DO%29N%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29N%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28C%29C%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28C%29C%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28C%29C%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CCCCN%29C%28%3DO%29N%5BC%40%40H%5D%28Cc1c%5BnH%5Dc2c1cccc2%29C%28%3DO%29N%5BC%40%40H%5D%28C%29C%28%3DO%29N%5BC%40%40H%5D%28CO%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28C%29C%29C%28%3DO%29N%5BC%40%40H%5D%28Cc3c%5BnH%5Dc4c3cccc4%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28%3DO%29N%29C%28%3DO%29N%5BC%40%40H%5D%28Cc5c%5BnH%5Dc6c5cccc6%29C%28%3DO%29N%5BC%40%40H%5D%28Cc7ccccc7%29C%28%3DO%29N%29NC%28%3DO%29%5BC%40H%5D%28CC%28C%29C%29NC%28%3DO%29%5BC%40H%5D%28CO%29NC%28%3DO%29%5BC%40H%5D%28Cc8cnc%5BnH%5D8%29NC%28%3DO%29%5BC%40H%5D%28%5BC%40%40H%5D%28C%29CC%29NC%28%3DO%29%5BC%40H%5D%28CC%28C%29C%29NC%28%3DO%29%5BC%40H%5D%28CO%29NC%28%3DO%29%5BC%40H%5D%28%5BC%40%40H%5D%28C%29O%29NC%28%3DO%29%5BC%40H%5D%28Cc9ccc%28cc9%29O%29NC%28%3DO%29C'" tppabs="https://chemapps.stolaf.edu/jmol/jmol.php?model=CC%5BC%40H%5D%28C%29%5BC%40%40H%5D%28C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CO%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29N%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28%3DO%29N%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29N%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29N%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CCCCN%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28%3DO%29N%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29N%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28C%29C%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28C%29C%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28C%29C%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CCCCN%29C%28%3DO%29N%5BC%40%40H%5D%28Cc1c%5BnH%5Dc2c1cccc2%29C%28%3DO%29N%5BC%40%40H%5D%28C%29C%28%3DO%29N%5BC%40%40H%5D%28CO%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28C%29C%29C%28%3DO%29N%5BC%40%40H%5D%28Cc3c%5BnH%5Dc4c3cccc4%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28%3DO%29N%29C%28%3DO%29N%5BC%40%40H%5D%28Cc5c%5BnH%5Dc6c5cccc6%29C%28%3DO%29N%5BC%40%40H%5D%28Cc7ccccc7%29C%28%3DO%29N%29NC%28%3DO%29%5BC%40H%5D%28CC%28C%29C%29NC%28%3DO%29%5BC%40H%5D%28CO%29NC%28%3DO%29%5BC%40H%5D%28Cc8cnc%5BnH%5D8%29NC%28%3DO%29%5BC%40H%5D%28%5BC%40%40H%5D%28C%29CC%29NC%28%3DO%29%5BC%40H%5D%28CC%28C%29C%29NC%28%3DO%29%5BC%40H%5D%28CO%29NC%28%3DO%29%5BC%40H%5D%28%5BC%40%40H%5D%28C%29O%29NC%28%3DO%29%5BC%40H%5D%28Cc9ccc%28cc9%29O%29NC%28%3DO%29C" class="external text external">Interactive image</a></span></li></ul></div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">SMILES</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2c1cccc2)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3c[nH]c4c3cccc4)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](Cc5c[nH]c6c5cccc6)C(=O)N[C@@H](Cc7ccccc7)C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](Cc8cnc[nH]8)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc9ccc(cc9)O)NC(=O)C</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">InChI</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">InChI=1S/C204H301N51O64/c1-20-102(15)166(253-195(310)137(75-100(11)12)239-200(315)150(93-258)251-190(305)143(82-112-90-215-95-219-112)248-203(318)167(103(16)21-2)254-196(311)138(76-101(13)14)240-201(316)151(94-259)252-204(319)168(105(18)260)255-197(312)139(221-106(19)261)78-108-45-47-113(262)48-46-108)202(317)233-131(58-68-164(280)281)178(293)228-130(57-67-163(278)279)182(297)250-149(92-257)198(313)232-125(52-62-155(210)266)179(294)245-145(84-157(212)268)191(306)229-124(51-61-154(209)265)175(290)224-122(49-59-152(207)263)173(288)226-126(53-63-159(270)271)176(291)222-120(43-31-33-69-205)172(287)244-144(83-156(211)267)192(307)231-127(54-64-160(272)273)177(292)225-123(50-60-153(208)264)174(289)227-128(55-65-161(274)275)180(295)235-134(72-97(5)6)185(300)237-133(71-96(3)4)184(299)230-129(56-66-162(276)277)181(296)236-135(73-98(7)8)187(302)247-147(86-165(282)283)194(309)223-121(44-32-34-70-206)171(286)241-140(79-109-87-216-117-40-28-25-37-114(109)117)183(298)220-104(17)170(285)249-148(91-256)199(314)238-136(74-99(9)10)186(301)242-142(81-111-89-218-119-42-30-27-39-116(111)119)189(304)246-146(85-158(213)269)193(308)243-141(80-110-88-217-118-41-29-26-38-115(110)118)188(303)234-132(169(214)284)77-107-35-23-22-24-36-107/h22-30,35-42,45-48,87-90,95-105,120-151,166-168,216-218,256-260,262H,20-21,31-34,43-44,49-86,91-94,205-206H2,1-19H3,(H2,207,263)(H2,208,264)(H2,209,265)(H2,210,266)(H2,211,267)(H2,212,268)(H2,213,269)(H2,214,284)(H,215,219)(H,220,298)(H,221,261)(H,222,291)(H,223,309)(H,224,290)(H,225,292)(H,226,288)(H,227,289)(H,228,293)(H,229,306)(H,230,299)(H,231,307)(H,232,313)(H,233,317)(H,234,303)(H,235,295)(H,236,296)(H,237,300)(H,238,314)(H,239,315)(H,240,316)(H,241,286)(H,242,301)(H,243,308)(H,244,287)(H,245,294)(H,246,304)(H,247,302)(H,248,318)(H,249,285)(H,250,297)(H,251,305)(H,252,319)(H,253,310)(H,254,311)(H,255,312)(H,270,271)(H,272,273)(H,274,275)(H,276,277)(H,278,279)(H,280,281)(H,282,283)/t102-,103-,104-,105+,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,166-,167-,168-/m0/s1<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Key:PEASPLKKXBYDKL-FXEVSJAOSA-N<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><sup><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup><span>&nbsp;</span>(what is this?)</span><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=399917793&page2=Enfuvirtide  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=399917793&page2=Enfuvirtide'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=399917793&page2=Enfuvirtide" class="external text external">(verify)</a></span></span></td></tr></tbody></table>
<p>Enfuvirtide therapy costs an estimated US$25,000 per year in the United States. Its cost and inconvenient dosing regimen are factors behind its use as a reserve, for salvage therapy in patients with multi-drug resistant HIV.</p>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Structural_formula">Structural formula</h2></summary>
    
<p><figure-inline><img src="../I/m/Enfuvirtid.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Enfuvirtid.svg.png" data-file-width="3816" data-file-height="362" data-file-type="drawing" height="47" width="500"></figure-inline></p>

<p>Ac-<a href="Tyrosine.htm" tppabs="https://ptable.com/wiki/compounds/A/Tyrosine" title="Tyrosine">Tyr</a>-<a href="Threonine.htm" tppabs="https://ptable.com/wiki/compounds/A/Threonine" title="Threonine">Thr</a>-<a href="Serine.htm" tppabs="https://ptable.com/wiki/compounds/A/Serine" title="Serine">Ser</a>-<a href="Leucine.htm" tppabs="https://ptable.com/wiki/compounds/A/Leucine" title="Leucine">Leu</a>-<a href="Isoleucine.htm" tppabs="https://ptable.com/wiki/compounds/A/Isoleucine" title="Isoleucine">Ile</a>-<a href="Histidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Histidine" title="Histidine">His</a>-Ser-Leu-Ile-<a href="Glutamic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Glutamic_acid" title="Glutamic acid">Glu</a>-Glu-Ser-<a href="Glutamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Glutamine" title="Glutamine">Gln</a>-<a href="Asparagine.htm" tppabs="https://ptable.com/wiki/compounds/A/Asparagine" title="Asparagine">Asn</a>-Gln-Gln-Glu-<a href="Lysine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lysine" title="Lysine">Lys</a>-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-<a href="Lysine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lysine" title="Lysine">Lys</a>-<a href="Tryptophan.htm" tppabs="https://ptable.com/wiki/compounds/A/Tryptophan" title="Tryptophan">Trp</a>-<a href="Alanine.htm" tppabs="https://ptable.com/wiki/compounds/A/Alanine" title="Alanine">Ala</a>-Ser-Leu-Trp-<a href="Asparagine.htm" tppabs="https://ptable.com/wiki/compounds/A/Asparagine" title="Asparagine">Asn</a>-Trp-<a href="Phenylalanine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenylalanine" title="Phenylalanine">Phe</a>-NH<sub>2</sub></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    
<p>Enfuvirtide originated at Duke University, where researchers formed a pharmaceutical company known as Trimeris.  Trimeris began development on enfuvirtide in 1996 and initially designated it <b>T-20</b>. In 1999, Trimeris entered into partnership with Hoffmann-La Roche to complete the development of the drug. It was approved by the U.S. Food and Drug Administration (FDA) on March 13, 2003<span class="mw-ref" id="cite_ref-1"><a href="#cite_note-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> as the first HIV fusion inhibitor, a new class of antiretroviral drugs. It was approved on the basis of two studies which compared the effect of optimized regimens of antiretroviral medication with and without the addition of enfuvirtide on serum viral load.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Pharmacology">Pharmacology</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Mechanism_of_action">Mechanism of action</h3></summary>
    
<p>Enfuvirtide works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected. A biomimetic peptide, enfuvirtide was designed to mimic components of the HIV-1 fusion machinery and displace them, preventing normal fusion. Drugs that disrupt fusion of virus and target cell are termed entry inhibitors or fusion inhibitors.</p>

<p>HIV binds to the host CD4+ cell receptor via the viral protein gp120; gp41, a viral transmembrane protein, then undergoes a conformational change that assists in the fusion of the viral membrane to the host cell membrane. Enfuvirtide binds to gp41 preventing the creation of an entry pore for the capsid of the virus, keeping it out of the cell.<span class="mw-ref" id="cite_ref-2"><a href="#cite_note-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>

<p>Enfuvirtide is also an activator of the chemotactic factor receptor, formyl peptide receptor 1, and thereby activates phagocytes and presumably other cells bearing this receptor (see formyl peptide receptors).<span class="mw-ref" id="cite_ref-pmid10339497_3-0"><a href="#cite_note-pmid10339497-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span>  The physiological significance of this activation is unknown.</p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Microbiology">Microbiology</h3></summary>
    
<p>Enfuvirtide is considered to be active against HIV-1 only. Low activity against HIV-2 isolates has been demonstrated <i>in vitro</i>.<span class="mw-ref" id="cite_ref-FuzeonPI_4-0"><a href="#cite_note-FuzeonPI-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>

<p>Variable susceptibility to enfuvirtide has been observed in clinical isolates, with acquired resistance the result of a mutated 10 amino acid motif in viral gp41. <span class="new">Primary resistance</span>, however, has yet to be observed.<span class="mw-ref" id="cite_ref-Greenberg2004_5-0"><a href="#cite_note-Greenberg2004-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Clinical_use">Clinical use</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Indications">Indications</h3></summary>
    
<p>Enfuvirtide is indicated for the treatment of HIV-1 infection, in combination therapy with other antiretrovirals, in patients where all other treatments have failed.<span class="mw-ref" id="cite_ref-AMH2006_6-0"><a href="#cite_note-AMH2006-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Dosage_forms">Dosage forms</h3></summary>
    
<p>By virtue of its peptide nature, enfuvirtide is marketed in injectable form. The lyophilised enfuvirtide powder must be reconstituted by the patient and administered twice daily by subcutaneous injection. Due to the chronic nature of this kind of therapy, this dosage form may be a major problem for the patient's adherence to this drug regimen.<span class="mw-ref" id="cite_ref-7"><a href="#cite_note-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Adverse_effects">Adverse effects</h3></summary>
    
<p>Common adverse drug reactions (≥1% of patients) associated with enfuvirtide therapy include: injection site reactions (pain, hardening of skin, erythema, nodules, cysts, itch; experienced by nearly all patients, particularly in the first week), peripheral neuropathy, insomnia, depression, cough, dyspnoea, anorexia, arthralgia, infections (including bacterial pneumonia) and/or eosinophilia. Various hypersensitivity reactions occur infrequently (0.1–1% of patients), symptoms of which include rash, fever, nausea, vomiting, chills, rigors, hypotension, elevated hepatic transaminases; and possibly more severe reactions including respiratory distress, glomerulonephritis and/or anaphylaxis – rechallenge is not recommended.<span class="mw-ref" id="cite_ref-AMH2006_6-1"><a href="#cite_note-AMH2006-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap"><ol class="mw-references references"><li id="cite_note-1"> <span id="mw-reference-text-cite_note-1" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021481  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021481'" tppabs="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021481" class="external text external">"Drugs@FDA: FDA Approved Drug Products – Fuzeon (Click on 'Approval Date(s) and History, Letters, Labels, Reviews for NDA 021481')"</a>. <i>accessdata.fda.gov</i>. United States Food and Drug Administration<span class="reference-accessdate">. Retrieved <span class="nowrap">6 January</span> 2019</span>.</cite></span></li><li id="cite_note-2"> <span id="mw-reference-text-cite_note-2" class="mw-reference-text"><cite id="CITEREFLalezariEronCarlsonCohen2003" class="citation journal cs1">Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC,  et al. (March 2003). "A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy". <i>AIDS</i>. <b>17</b> (5): 691–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2F00002030-200303280-00007  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2F00002030-200303280-00007'" tppabs="https://doi.org/10.1097%2F00002030-200303280-00007" class="external text external">10.1097/00002030-200303280-00007</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12646792  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12646792'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12646792" class="external text external">12646792</a>.</cite></span></li><li id="cite_note-pmid10339497-3"> <span id="mw-reference-text-cite_note-pmid10339497-3" class="mw-reference-text"><cite id="CITEREFSuGongGaoShen1999" class="citation journal cs1">Su SB, Gong WH, Gao JL, Shen WP, Grimm MC, Deng X,  et al. (June 1999). "T20/DP178, an ectodomain peptide of human immunodeficiency virus type 1 gp41, is an activator of human phagocyte N-formyl peptide receptor". <i>Blood</i>. <b>93</b> (11): 3885–92. doi:<a href="javascript:if(confirm('https://doi.org/10.1182%2Fblood.V93.11.3885  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1182%2Fblood.V93.11.3885'" tppabs="https://doi.org/10.1182%2Fblood.V93.11.3885" class="external text external">10.1182/blood.V93.11.3885</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10339497  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10339497'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10339497" class="external text external">10339497</a>.</cite></span></li><li id="cite_note-FuzeonPI-4"> <span id="mw-reference-text-cite_note-FuzeonPI-4" class="mw-reference-text">Roche Products Pty Ltd. Fuzeon (Australian Approved Product Information). Dee Why (NSW): Roche; 2005.</span></li><li id="cite_note-Greenberg2004-5"> <span id="mw-reference-text-cite_note-Greenberg2004-5" class="mw-reference-text"><cite id="CITEREFGreenbergCammack2004" class="citation journal cs1">Greenberg ML, Cammack N (August 2004). <a href="javascript:if(confirm('https://doi.org/10.1093/jac/dkh330  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093/jac/dkh330'" tppabs="https://doi.org/10.1093/jac/dkh330" class="external text external">"Resistance to enfuvirtide, the first HIV fusion inhibitor"</a>. <i>The Journal of Antimicrobial Chemotherapy</i>. <b>54</b> (2): 333–40. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1093%2Fjac%2Fdkh330  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093%2Fjac%2Fdkh330'" tppabs="https://doi.org/10.1093%2Fjac%2Fdkh330" class="external text external">10.1093/jac/dkh330</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15231762  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15231762'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15231762" class="external text external">15231762</a>.</cite></span></li><li id="cite_note-AMH2006-6"> <span id="mw-reference-text-cite_note-AMH2006-6" class="mw-reference-text"><cite id="CITEREFRossi2006" class="citation book cs1">Rossi S, ed. (2006). <i>Australian Medicines Handbook</i>. Adelaide: Australian Medicines Handbook Pty Ltd. ISBN<span>&nbsp;</span><bdi>0-9757919-2-3</bdi>.</cite></span></li><li id="cite_note-7"> <span id="mw-reference-text-cite_note-7" class="mw-reference-text"><cite id="CITEREFKlein2003" class="citation web cs1">Klein R (13 March 2003). <a href="javascript:if(confirm('https://web.archive.org/web/20090825164901/https://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm125088.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20090825164901/https://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm125088.htm'" tppabs="https://web.archive.org/web/20090825164901/https://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm125088.htm" class="external text external">"FDA approves Fuzeon"</a>. <i>fda.gov</i>. Archived from <a href="javascript:if(confirm('https://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm125088.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm125088.htm'" tppabs="https://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm125088.htm" class="external text external">the original</a> on 25 August 2009<span class="reference-accessdate">. Retrieved <span class="nowrap">2 July</span> 2011</span>.</cite></span></li></ol></div></div>

<div role="navigation" class="navbox" aria-labelledby="Antiviral_drugs:_antiretroviral_drugs_used_against_HIV_(primarily_J05)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Antiviral_drugs:_antiretroviral_drugs_used_against_HIV_(primarily_J05)" style="font-size:114%;margin:0 4em">Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Entry/fusion inhibitors <br> <i>(Discovery and development)</i></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>gp41</i> (<a href="Enfuvirtide.htm" tppabs="https://ptable.com/wiki/compounds/A/Enfuvirtide" title="Enfuvirtide">Enfuvirtide (ENF, T-20)</a>)</li>
<li><i>CCR5</i> (<a href="Maraviroc.htm" tppabs="https://ptable.com/wiki/compounds/A/Maraviroc" title="Maraviroc">Maraviroc (MVC)</a></li>
<li>Vicriviroc<sup>†</sup>, Cenicriviroc<sup>†</sup>, PRO 140<sup>†</sup>)</li>
<li><i>CD4</i> (Ibalizumab<sup>†</sup>, UB421<sup>§</sup>)</li>
<li><i>gp120</i> (Fostemsavir)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Reverse-transcriptase<br> inhibitors (RTIs)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Nucleoside and<br> nucleotide (NRTI)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Nucleoside analogues/NRTIs:</i>  <a href="Abacavir.htm" tppabs="https://ptable.com/wiki/compounds/A/Abacavir" title="Abacavir">Abacavir (ABC)</a>°<sup>#</sup></li>
<li><a href="Didanosine.htm" tppabs="https://ptable.com/wiki/compounds/A/Didanosine" title="Didanosine">Didanosine (ddI)</a></li>
<li><a href="Emtricitabine.htm" tppabs="https://ptable.com/wiki/compounds/A/Emtricitabine" title="Emtricitabine">Emtricitabine (FTC)</a>°</li>
<li><a href="Lamivudine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lamivudine" title="Lamivudine">Lamivudine (3TC)</a>°<sup>#</sup></li>
<li><a href="Stavudine.htm" tppabs="https://ptable.com/wiki/compounds/A/Stavudine" title="Stavudine">Stavudine (d4T)</a><sup>#</sup></li>
<li><a href="Zidovudine.htm" tppabs="https://ptable.com/wiki/compounds/A/Zidovudine" title="Zidovudine">Zidovudine (AZT, ZDV)</a><sup>#</sup></li>
<li>Amdoxovir<sup>†</sup></li>
<li>Apricitabine<sup>†</sup></li>
<li>Censavudine<sup>†</sup></li>
<li>Elvucitabine<sup>†</sup></li>
<li>Islatravir (EFdA)<sup>§</sup></li>
<li>Racivir<sup>†</sup></li>
<li>Stampidine<sup>†</sup></li>
<li><a href="Zalcitabine.htm" tppabs="https://ptable.com/wiki/compounds/A/Zalcitabine" title="Zalcitabine">Zalcitabine (ddC)</a><sup>◊</sup></li></ul>

<ul><li><i>Nucleotide analogues/NtRTIs:</i>  Tenofovir disoproxil (TDF)°<sup>#</sup></li>
<li>Tenofovir alafenamide (TAF)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Non-nucleoside (NNRTI)<br><i>(Discovery and development)</i></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">1<sup>st</sup> generation</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Efavirenz.htm" tppabs="https://ptable.com/wiki/compounds/A/Efavirenz" title="Efavirenz">Efavirenz (EFV)</a>°<sup>#</sup></li>
<li><a href="Nevirapine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nevirapine" title="Nevirapine">Nevirapine (NVP)</a><sup>#</sup></li>
<li><a href="Delavirdine.htm" tppabs="https://ptable.com/wiki/compounds/A/Delavirdine" title="Delavirdine">Delavirdine (DLV)</a><sup>◊</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">2<sup>nd</sup> generation</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>diarylpyrimidines</i>
<ul><li>Etravirine (ETR)</li>
<li>Rilpivirine (RPV)°</li></ul></li>
<li>Doravirine°</li></ul>
</div></td></tr></tbody></table><div></div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Integrase inhibitors<br>(Integrase strand transfer inhibitors (INSTI))</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Dolutegravir (DTG)°</li>
<li>Elvitegravir (EVG)°</li>
<li>Raltegravir (RAL)°</li>
<li>BI 224436<sup>†</sup></li>
<li>Cabotegravir<sup>†</sup></li>
<li>Bictegravir (BIC)<sup>†</sup></li>
<li>MK-2048<sup>†</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Maturation inhibitors</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Bevirimat<sup>†</sup></li>
<li>BMS-955176<sup>§</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Protease Inhibitors (PI)<br><i>(Discovery and development)</i></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">1<sup>st</sup> generation</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Amprenavir.htm" tppabs="https://ptable.com/wiki/compounds/A/Amprenavir" title="Amprenavir">Amprenavir (APV)</a><sup>◊</sup></li>
<li><a href="Fosamprenavir.htm" tppabs="https://ptable.com/wiki/compounds/A/Fosamprenavir" title="Fosamprenavir">Fosamprenavir (FPV)</a></li>
<li><a href="Indinavir.htm" tppabs="https://ptable.com/wiki/compounds/A/Indinavir" title="Indinavir">Indinavir (IDV)</a><sup>◊</sup></li>
<li><a href="Lopinavir.htm" tppabs="https://ptable.com/wiki/compounds/A/Lopinavir" title="Lopinavir">Lopinavir (LPV)</a></li>
<li><a href="Nelfinavir.htm" tppabs="https://ptable.com/wiki/compounds/A/Nelfinavir" title="Nelfinavir">Nelfinavir (NFV)</a></li>
<li><a href="Ritonavir.htm" tppabs="https://ptable.com/wiki/compounds/A/Ritonavir" title="Ritonavir">Ritonavir (RTV)</a><sup>#</sup></li>
<li><a href="Saquinavir.htm" tppabs="https://ptable.com/wiki/compounds/A/Saquinavir" title="Saquinavir">Saquinavir (SQV)</a><sup>#</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">2<sup>nd</sup> generation</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Atazanavir.htm" tppabs="https://ptable.com/wiki/compounds/A/Atazanavir" title="Atazanavir">Atazanavir (ATV)</a>°<sup>#</sup></li>
<li><a href="Darunavir.htm" tppabs="https://ptable.com/wiki/compounds/A/Darunavir" title="Darunavir">Darunavir (DRV)</a>°<sup>#</sup></li>
<li><a href="Tipranavir.htm" tppabs="https://ptable.com/wiki/compounds/A/Tipranavir" title="Tipranavir">Tipranavir (TPV)</a></li>
<li>TMC-310911<sup>§</sup></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Combined formulations</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Abacavir/lamivudine°<sup>#</sup></li>
<li>Abacavir/dolutegravir/lamivudine°</li>
<li>Abacavir/lamivudine/zidovudine</li>
<li>Atazanavir/cobicistat</li>
<li>Bictegravir/emtricitabine/tenofovir alafenamide</li>
<li>Darunavir/cobicistat</li>
<li>Darunavir/cobicistat/emtricitabine/tenofovir alafenamide</li>
<li>Dolutegravir/lamivudine</li>
<li>Dolutegravir/lamivudine/tenofovir</li>
<li>Dolutegravir/rilpivirine</li>
<li>Doravirine/lamivudine/tenofovir</li>
<li>Efavirenz/emtricitabine/tenofovir°<sup>#</sup></li>
<li>Efavirenz/lamivudine/tenofovir<sup>#</sup></li>
<li>Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide</li>
<li>Elvitegravir/cobicistat/emtricitabine/tenofovir°</li>
<li>Emtricitabine/tenofovir alafenamide</li>
<li>Emtricitabine/rilpivirine/tenofovir alafenamide</li>
<li>Emtricitabine/rilpivirine/tenofovir°</li>
<li>Emtricitabine/tenofovir°<sup>#</sup></li>
<li>Lamivudine/nevirapine/stavudine<sup>#</sup></li>
<li>Lamivudine/nevirapine/zidovudine<sup>#</sup></li>
<li>Lamivudine/raltegravir</li>
<li>Lamivudine/tenofovir</li>
<li>Lamivudine/zidovudine<sup>#</sup></li>
<li>Lopinavir/ritonavir°<sup>#</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Pharmacokinetic boosters</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Cobicistat (c)</li>
<li><a href="Ritonavir.htm" tppabs="https://ptable.com/wiki/compounds/A/Ritonavir" title="Ritonavir">Ritonavir (r)</a><sup>#</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Experimental agents</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Uncoating inhibitors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>TRIM5alpha (gene)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Transcription inhibitors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Tat antagonists</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Translation inhibitors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Trichosanthin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"> BNAbs</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Elipovimab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Abzyme</li>
<li>BIT225<sup>†</sup></li>
<li>Calanolide A</li>
<li>Ceragenin</li>
<li>Cyanovirin-N</li>
<li>Diarylpyrimidines</li>
<li><a href="Epigallocatechin_gallate.htm" tppabs="https://ptable.com/wiki/compounds/A/Epigallocatechin_gallate" title="Epigallocatechin gallate">Epigallocatechin gallate (EGCG)</a></li>
<li><a href="Foscarnet.htm" tppabs="https://ptable.com/wiki/compounds/A/Foscarnet" title="Foscarnet">Foscarnet</a></li>
<li>Fosdevirine<sup>†</sup></li>
<li>Griffithsin</li>
<li><a href="Hydroxycarbamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydroxycarbamide" title="Hydroxycarbamide">Hydroxycarbamide</a></li>
<li>KP-1461<sup>†</sup></li>
<li><a href="Miltefosine.htm" tppabs="https://ptable.com/wiki/compounds/A/Miltefosine" title="Miltefosine">Miltefosine</a></li>
<li>Portmanteau inhibitors</li>
<li>Scytovirin</li>
<li>Seliciclib<sup>†</sup></li>
<li>Synergistic enhancers</li>
<li>Tre recombinase</li>
<li>Zinc finger protein transcription factor</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Failed agents</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Aplaviroc</li>
<li>Atevirdine</li>
<li>Brecanavir</li>
<li>Capravirine</li>
<li>Dexelvucitabine</li>
<li>Droxinavir</li>
<li>Lasinavir</li>
<li>Emivirine</li>
<li>Lersivirine</li>
<li>Lodenosine</li>
<li>Loviride</li>
<li>Mozenavir</li>
<li><span class="new">Palinavir</span></li>
<li><span class="new">Telinavir</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;"><div><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div> °DHHS <i>recommended</i> initial regimen options. <sup>◊</sup>Formerly or rarely used agent.<br></div></td></tr></tbody></table></div>





<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-06-27" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Enfuvirtide&oldid=964849766  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Enfuvirtide&oldid=964849766'" tppabs="https://en.wikipedia.org/wiki/?title=Enfuvirtide&oldid=964849766">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>